Table of contents
- Trial overview
- Acne studies
- Cancer studies
- Study designs and phases
- Main endpoints measured
- Who participates in these trials
- Key patient takeaways
Trial overview
The trial data show that Tretinoin is being studied in very different diseases, not just one condition.[1] The main areas are acne, melanoma, acute myeloid leukemia, acute promyelocytic leukemia, oligometastatic solid cancer, and head and neck squamous cell carcinoma.[1]
These studies include both interventional trials, where researchers assign treatments, and different comparison designs such as placebo-controlled and active-controlled studies.[1][2] The trials range from early Phase 1 research to larger Phase 3 studies.[1]
Acne studies
Several Phase 3 trials are focused on acne, including acne vulgaris and papulopustular acne.[1][2] In these studies, Tretinoin is tested in gel form together with clindamycin, and the results are compared with a reference product or with a vehicle, which is a look-alike gel without the active medicine.[1][2]
One completed multicenter trial compared clindamycin + tretinoin/Verisfield gel with Acnatac®/Meda gel and placebo in 600 people with acne vulgaris.[1] Another authorised Phase 3 trial is studying a similar clindamycin and Tretinoin gel in 675 patients with papulopustular acne.[2]
The main acne outcomes are changes in facial lesion counts over 12 weeks, including inflammatory lesions such as papules and pustules, and non-inflammatory lesions such as open and closed comedones.[1][2] These outcomes help show whether the treatment reduces visible acne spots over time.[1][2]
Cancer studies
Most cancer trials with Tretinoin are early-phase studies that test it with other treatments.[3][4][5][6][7][8][9]
In melanoma, Tretinoin appears in Phase 1 studies for stage IIIB, IIIC, and IIID melanoma and for PD-1 refractory melanoma, which means melanoma that no longer responds to PD-1 treatment.[3][4][5] These studies combine Tretinoin with drugs such as pembrolizumab, lenvatinib, vibostolimab, quavonlimab, and other investigational agents.[3][4][5]
The melanoma trials mainly measure adverse events, treatment stopping because of side effects, and objective response rate, which means how many patients have a measurable tumor response.[3][4][5] One study also looks at pathological complete response, meaning no cancer is found in the tissue after treatment.[3]
In leukemia, one Phase 3 trial in newly diagnosed acute myeloid leukemia compares all-trans retinoic acid, also called ATRA, with placebo when added to decitabine and venetoclax, and its main endpoint is overall survival.[6] Another study in children and adolescents with acute promyelocytic leukemia tests ATRA with arsenic trioxide, and in some higher-risk patients also with gemtuzumab ozogamicin.[7]
The pediatric leukemia trial measures event-free survival, which includes failure to reach remission, relapse, or death, and it aims to understand results over several years after diagnosis.[7] This makes it a long-term outcome study, not only a short safety check.[7]
In head and neck cancer, a Phase 3 trial studies Tretinoin, also listed as all-trans retinoic acid, together with radiotherapy strategies in patients with lateralised oropharyngeal, laryngeal, and hypopharyngeal squamous cell carcinoma.[8] Its main endpoint is event-free survival.[8]
Another Phase 1 trial in oligometastatic solid cancer studies Tretinoin with stereotactic body radiotherapy, which is a highly focused form of radiation treatment.[9] This study has two main goals: safety in the first part and protection against radiation-related lymphopenia, which means a drop in lymphocytes, a type of white blood cell.[9]
Study designs and phases
The acne studies are designed as multicenter, randomized, double-blind, parallel trials, which are strong methods for comparing treatments fairly.[1] They also use active controls and placebo controls to show whether the Tretinoin-containing gel works better than comparison treatments.[1][2]
The cancer studies use different early and late development phases based on the question being asked.[3][4][5][6][7][8][9] Phase 1 trials focus on safety and tolerability, while Phase 2 and Phase 3 trials study whether the treatment helps patients and whether the benefit is strong enough for larger testing.[3][4][5][6][7][8][9]
Main endpoints measured
The acne studies measure the percent change in inflammatory and non-inflammatory lesion counts from baseline to Week 12.[1][2] Baseline means the first measurement before treatment starts.[1][2]
The melanoma studies measure safety endpoints such as adverse events and dose-limiting toxicity, plus response outcomes like objective response rate and pathological complete response.[3][4][5] Dose-limiting toxicity means a side effect serious enough to limit treatment in the early part of a study.[4][5]
The leukemia and head and neck cancer studies focus on survival outcomes, especially overall survival and event-free survival.[6][7][8] The oligometastatic solid cancer study adds a special safety outcome for lymphopenia after treatment.[9]
Who participates in these trials
Trial participants are chosen based on the disease being studied.[1][2][3][4][5][6][7][8][9]
People with acne vulgaris or papulopustular acne join the skin studies, which compare Tretinoin-containing gels with reference treatment or vehicle.[1][2]
Adults with stage IIIB, IIIC, IIID, or PD-1 refractory melanoma join the melanoma trials, where Tretinoin is tested in combination with other cancer medicines.[3][4][5]
Adults with newly diagnosed acute myeloid leukemia join the DECIDER-2 trial if they are not eligible for induction chemotherapy, which is the standard intensive first treatment.[6]
Children and adolescents with acute promyelocytic leukemia join the pediatric study, which tests ATRA-based treatment plans.[7]
People with lateralised oropharyngeal, laryngeal, or hypopharyngeal squamous cell carcinoma join the head and neck cancer trial, and people with oligometastatic solid cancer join the radiotherapy study.[8][9]
Key patient takeaways
The trial data show that Tretinoin is being studied in both common skin disease and several serious cancers.[1][2][3][4][5][6][7][8][9]
For acne, the main question is whether Tretinoin-containing gels reduce lesion counts better than reference products or placebo.[1][2] For cancer, the main questions are safety, response, survival, and whether Tretinoin can help when added to other treatments.[3][4][5][6][7][8][9]
Across the studies, the evidence base includes randomized Phase 3 acne trials and smaller early-phase cancer trials, giving a broad view of how Tretinoin is being tested in modern clinical research.[1][2][3][4][5][6][7][8][9]
